Corcept Therapeutics Incorporated
CORT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $207,638 | $194,430 | $157,214 | $181,890 |
| % Growth | 6.8% | 23.7% | -13.6% | – |
| Cost of Goods Sold | $4,596 | $3,433 | $2,403 | $2,956 |
| Gross Profit | $203,042 | $190,997 | $154,811 | $178,934 |
| % Margin | 97.8% | 98.2% | 98.5% | 98.4% |
| R&D Expenses | $68,846 | $60,471 | $60,735 | $70,300 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $123,977 | $103,851 | $90,660 | $83,372 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $192,823 | $164,322 | $151,395 | $153,672 |
| Operating Income | $10,219 | $26,675 | $3,416 | $25,262 |
| % Margin | 4.9% | 13.7% | 2.2% | 13.9% |
| Other Income/Exp. Net | $5,024 | $5,017 | $6,202 | $6,698 |
| Pre-Tax Income | $15,243 | $31,692 | $9,618 | $31,960 |
| Tax Expense | $4,425 | -$3,457 | -$10,929 | $1,214 |
| Net Income | $19,359 | $35,149 | $20,288 | $30,389 |
| % Margin | 9.3% | 18.1% | 12.9% | 16.7% |
| EPS | 0.19 | 0.33 | 0.19 | 0.29 |
| % Growth | -42.4% | 73.7% | -34.5% | – |
| EPS Diluted | 0.16 | 0.29 | 0.17 | 0.26 |
| Weighted Avg Shares Out | 103,545 | 104,111 | 104,106 | 103,643 |
| Weighted Avg Shares Out Dil | 119,439 | 120,485 | 119,819 | 118,459 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,024 | $5,017 | $6,202 | $6,698 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $477 | $469 | $462 | $460 |
| EBITDA | $15,720 | $27,144 | $3,878 | $25,722 |
| % Margin | 7.6% | 14% | 2.5% | 14.1% |